Format

Send to

Choose Destination
Int J Colorectal Dis. 2014 Dec;29(12):1527-34. doi: 10.1007/s00384-014-2030-8. Epub 2014 Oct 21.

Prospective, randomized, controlled, proof-of-concept study of the Ghrelin mimetic ipamorelin for the management of postoperative ileus in bowel resection patients.

Author information

1
Department of Colon and Rectal Surgery Ochsner Clinic Foundation, New Orleans, Louisiana, The University of Queensland School of Medicine Ochsner Clinical School, Brisbane, Australia, 1514 Jefferson Highway, 70121, New Orleans, Louisiana, USA, dbeckmd@aol.com.

Abstract

BACKGROUND:

Postoperative ileus is a significant clinical challenge lacking effective management strategies. Ghrelin-receptor stimulation has promotility effects in the upper and lower gastrointestinal tract.

OBJECTIVE:

This proof-of-concept, phase 2, randomized study evaluated the safety and efficacy of the ghrelin-receptor agonist ipamorelin in the treatment of postoperative ileus following abdominal surgery (ClinicalTrials.gov NCT00672074).

DESIGN:

The design was a multicenter, double-blind, placebo-controlled, clinical trial.

SETTINGS:

The settings include hospital inpatients.

PATIENTS:

The patients were adults undergoing small and large bowel resection by open or laparoscopic surgery.

INTERVENTION:

The intervention was intravenous infusions of 0.03-mg/kg ipamorelin vs placebo twice daily, on postoperative day 1 to 7 or hospital discharge.

MAIN OUTCOME MEASURES:

Safety was assessed by monitoring adverse events and laboratory tests. The key efficacy endpoint was time from first dose of study drug to tolerance of a standardized solid meal.

RESULTS:

One hundred seventeen patients were enrolled, of whom 114 patients composed the safety and modified intent-to-treat populations. Demographic and disease characteristics were balanced between groups. Overall incidence of any treatment-emergent adverse events was 87.5 % in the ipamorelin group and 94.8 % in placebo group. Median time to first tolerated meal was 25.3 and 32.6 h in the ipamorelin and placebo groups, respectively (pā€‰=ā€‰0.15).

LIMITATIONS:

This proof of concept study was small and enrolled patients with a broad range of underlying conditions.

CONCLUSIONS:

Ipamorelin 0.03-mg/kg twice daily for up to 7 days was well tolerated. There were no significant differences between ipamorelin and placebo in the key and secondary efficacy analyses.

PMID:
25331030
DOI:
10.1007/s00384-014-2030-8
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Springer
Loading ...
Support Center